A recent study unveils the potential of a new combination therapy in enhancing treatment outcomes for patients with recurrent or metastatic cervical cancer.
Investigators compared the effectiveness of camrelizumab combined with famitinib against camrelizumab alone and standard chemotherapy, aiming to provide a more effective treatment option for affected individuals.
Study Design and Methods
The randomized trial involved patients with previously treated recurrent or metastatic cervical cancer, assigning them to receive either camrelizumab with famitinib, camrelizumab alone, or chemotherapy as chosen by the investigator. The primary metric assessed was the objective response rate, evaluated by a blinded independent central review.
Clinical Outcomes and Safety
Results demonstrated a significant increase in the objective response rate for the combination therapy group at 41%, compared to 24.1% for camrelizumab alone. Additionally, the median progression-free survival was extended to 8.1 months with the combination treatment. Overall survival times also favored the combination therapy, reaching 20.2 months.
• Combination therapy led to a 16.9% higher response rate than camrelizumab alone.
• Progression-free survival improved by over four months with the combination.
• The safety profile remained manageable, despite a higher incidence of certain grade 3 adverse events.
The combination of camrelizumab and famitinib not only enhances antitumor activity but also maintains a manageable safety profile, offering a promising new treatment avenue for patients with recurrent or metastatic cervical cancer.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
